 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning Devgen NV
|
-
Devgen completes acquisition of seed assets from Monsanto subsidiaries in India and Monsanto Company subscribes to Devgen shares
(11/05/2007)
Devgen announced it has completed the acquisition of certain Monsanto assets in India. Devgen also announced that Monsanto Company subscribed to 1,045,400 Devgen shares at a price of EUR 17.22 per share.Devgen has finalized the acquisition of ...
-
Monsanto Company signs share subscription agreement with Devgen
(09/17/2007)
Devgen and Monsanto Company announced that they have signed an agreement in which Monsanto has agreed, subject to certain customary conditions, to subscribe to 1,045,400 Devgen shares at 17.22EUR/share, totaling 18 million EUR (25 million $) and ...
-
Devgen announces promising results of its nematicide field trials in banana plantations
(05/11/2007)
Devgen NV provided a business update highlighting progress with its portfolio of programs and some key financials. In particular, Devgen announced the results of exploratory trials with its nematicide product under development in banana plantations. ...
-
Devgen receives IWT grant to support its obesity drug discovery program
(02/27/2007)
Devgen has been awarded a 0.9 million Euro technology grant from the Flanders government through IWT (Institute for the Promotion of Innovation by Science and Technology in Flanders) to develop new targets and therapeutic solutions for the treatment ...
-
Devgen and Monsanto Company announce research and technology agreements
(02/07/2007)
Devgen N.V. and Monsanto Company announced that they have entered into a five-year research and development (R&D) agreement and a five-year technology exchange agreement. These agreements shall enable the parties to identify potential product ...
-
Devgen drug candidates may promise breakthrough in the treatment of rheumatoid arthritis and other inflammatory diseases
(08/25/2006)
Devgen announced that, following encouraging results from studies in animals, one of its preclinical programs may show promise for the treatment of inflammatory diseases. Devgen scientists have discovered compounds that inhibit the secretion of ...
-
DuPont and Devgen Extend Research Collaboration on Pest Resistance Solutions
(05/19/2006)
Research focused on multi-billion dollar nematode challenge for crops, including soybeans
DuPont, through its subsidiary Pioneer Hi-Bred International, Inc., and Devgen announced the extension of a research collaboration to develop superior crop varieties with innate resistance to plant pests, such as plant parasitic nematodes, which are ...
|
|
|
|
|
Top
